Phillip Koo: Welcome to UroToday and our special feature on practical aspects of starting a theranostics clinic. And we are very fortunate to have with us today, Dr. Kendra Harris, who is Chair of Radiation/Oncology at Tulane, and also Charlotte Manogue, who is the GU Program Manager at the Tulane Cancer Center. So thank you, guys, […]
Phillip Koo: Hello. My name is Phillip Koo from Banner MD Anderson Cancer Center in Phoenix, Arizona. I’d like to welcome you all to UroToday for a special feature that we have focusing on radioligand therapies in the clinic. And really focusing on the practical aspects of these therapies, especially since we now have the […]
Phillip Koo: Hello, my name is Phillip Koo from Banner MD Anderson Cancer Center in Phoenix, Arizona. I’d like to welcome you all to UroToday for a special feature that we have focusing on radioligand therapies in the clinic, and really focusing on the practical aspects of these therapies, especially since we now have the […]
Kendra Harris: So, the dose arrived this morning, delivered by courier in a large box. The Lutetium arrives in a vial which is then put into what we call a “pig,” which is an additional mechanism to shield it. Those are empty. The one that is full is behind the shielding. My physicists have already […]
Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab.
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
In our institution, a prospective observational trial testing micro-RNA (miRNA) and ARV7 mutational status in metastatic, castration resistant prostate cancer (mCRPC), is currently recruiting (PRIMERA trial, NCT04188275).
The purpose of this study was to describe the uptake, discontinuation and variation of active surveillance (AS) by provider and patient level characteristics. This observational, population-based study used linked administrative databases and pathology reports to identify all men diagnosed with Gleason score ≤6 prostate cancer (PC) between January 1, 2008 and December 31, 2014 in […]
Addition of a brachytherapy boost to external beam radiation therapy (EBRT) reduces prostate cancer (PCa) recurrence at the expense of genitourinary (GU) toxicity. Whether brachytherapy boost technique, specifically low-dose-rate (LDR-BT) versus high-dose-rate (HDR-BT), impacts treatment-related toxicity is unclear.
To assess the safety and performance of a MRI-directed diagnostic pathway for patients with first-time suspicion of prostate cancer in a non-university hospital. Between May 2017 and December 2018 all biopsy-naive patients examined in our hospital followed a MRI-directed diagnostic work-up algorithm based on PI-RADS score.
